» Articles » PMID: 38751528

Five-year Survival in Luminal Breast Cancer Patients: Relation with Intratumoral Activity of Proteasomes

Overview
Date 2024 May 16
PMID 38751528
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of the study was to analyze the relationship between the caspase-like (CL) and chymotrypsin-like (ChTL) activities of proteasomes and the 5-year overall and metastasis-free survival rates in patients with luminal breast cancer.

Methods: The study included 117 patients with primary operable invasive breast cancer (TNM). Tissue samples from breast cancer patients were obtained as a result of the radical mastectomy or breast conserving surgery, which was a first line of therapy. The ChTL and CL proteasomes activities in the tumor tissue and in the surrounding adjacent breast tissues were assessed using the fluorometric method. The coefficients of ChTL (cChTL) and CL (cCL) proteasomes activities were also determined. The coefficients were calculated as the ratio of the corresponding proteasomes activity in the tumor tissue to the surrounding adjacent breast tissues. Within 5 years of follow-up, hematogenous metastases occurred in 14% of patients with luminal A breast cancer, in 31% of patients with luminal B human epidermal growth factor receptor-2 (HER-2) negative and in 23% of patients with luminal B HER-2 positive breast cancers. The study protocol was approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center. Written informed consent was obtained from all patients.

Results: An increase in the ChTL and CL proteasomes activities was shown in all studied molecular subtypes of breast cancer compared to adjacent tissues. It was found that the cChTL of >35.9 U/mg protein and the cCL of >2.21 in breast cancer patients were associated with the development of distant metastases. In patients with luminal A breast cancer, the 5-year metastasis-free survival rates were associated only with the value of cCL of proteasomes (log-rank test: P=0.008). In patients with luminal B HER-2 negative breast cancer, the 5-year metastasis-free survival rates were associated with the levels of ChTL and cCL proteasomes activities (log-rank test: P=0.02 and P=0.04, respectively).

Conclusions: The data obtained on the correlation of 5-year metastasis-free survival rates with the level of proteasomes activities indicate the possibility of their use as additional prognostic criteria for breast cancer.

Citing Articles

Association of Proteasome Activity and Pool Heterogeneity with Markers Determining the Molecular Subtypes of Breast Cancer.

Kondakova I, Sereda E, Sidenko E, Vtorushin S, Vedernikova V, Burov A Cancers (Basel). 2025; 17(1.

PMID: 39796785 PMC: 11720674. DOI: 10.3390/cancers17010159.


Development and validation of a predictive nomogram for the specific mortality risk of luminal B breast cancer patients: a competing risk model based on real populations.

Zhao H, Yan H, Chen L, Li Y Transl Cancer Res. 2023; 12(4):965-979.

PMID: 37180675 PMC: 10175002. DOI: 10.21037/tcr-23-484.

References
1.
Zhang P, Zhao J, Li H, Man J, He K, Zhou T . CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 2007; 26(7):1831-42. PMC: 1847652. DOI: 10.1038/sj.emboj.7601602. View

2.
Nagpal N, Ahmad H, Molparia B, Kulshreshtha R . MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis. 2013; 34(8):1889-99. DOI: 10.1093/carcin/bgt107. View

3.
Schroeder R, Stevens C, Sridhar J . Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules. 2014; 19(9):15196-212. PMC: 6270702. DOI: 10.3390/molecules190915196. View

4.
Powers G, Rajbhandari P, Solodin N, Bickford B, Alarid E . The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene. PLoS One. 2013; 8(12):e81110. PMC: 3855213. DOI: 10.1371/journal.pone.0081110. View

5.
Thangarajah F, Enninga I, Malter W, Hamacher S, Markiefka B, Richters L . A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases. Anticancer Res. 2017; 37(4):1957-1964. DOI: 10.21873/anticanres.11536. View